A protein phosphatase feedback mechanism regulates the basal phosphorylation of Chk2 kinase in the absence of DNA damage  by Carlessi, Luigi et al.
Biochimica et Biophysica Acta 1803 (2010) 1213–1223
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamcrA protein phosphatase feedback mechanism regulates the basal phosphorylation of
Chk2 kinase in the absence of DNA damage
Luigi Carlessi, Giacomo Buscemi, Enrico Fontanella, Domenico Delia ⁎
Dept of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Via Amadeo 42, 20133 Milano, Italy⁎ Corresponding author. Tel.: +39 02 23902641.
E-mail address: domenico.delia@istitutotumori.mi.it
0167-4889/$ – see front matter © 2010 Elsevier B.V. A
doi:10.1016/j.bbamcr.2010.06.002a b s t r a c ta r t i c l e i n f oArticle history:
Received 15 March 2010
Received in revised form 20 May 2010
Accepted 14 June 2010
Available online 22 June 2010
Keywords:
Cell cycle checkpoints
DNA damage responses
Chk2
Kinase inhibitors
Protein phosphatasesThe checkpoint kinase Chk2 is an effector component of the ATM-dependent DNA damage response (DDR)
pathway. The activation of Chk2 by genotoxic stress involves its phosphorylation on T68 by ATM and
additional auto/transphosphorylations. Here we demonstrate that in unperturbed cells, chemical inhibition
of Chk2 by VRX0466617 (VRX) enhances the phosphorylation of Chk2-T68 throughout the cell cycle phases.
This event, dependent on the presence of ATM and catalytically functional Chk2, is not consequential to DNA
damage, as neither γ-H2AX nuclear foci nor increased ATM activation is detected in VRX-treated cells,
suggesting the involvement of other regulatory proteins. As serine/threonine protein phosphatases (PPs)
regulate the phosphorylation and deactivation of proteins of the DDR pathway, we analyzed their role in
phospho-T68-Chk2 regulation. We found that intracellular inhibition of PP1 and PP2A-like activities by
okadaic acid markedly raised the accumulation of Chk2-pT68 without DNA damage induction, and this
phenomenon was also seen when PP1-C, PP2A-C, and Wip1/PPM1D were simultaneously knockdown by
siRNA. Altogether, these data indicate a novel mechanism in undamaged cells where PPs function to
maintain the balance between ATM and its direct substrate Chk2 through a regulatory circuit.(D. Delia).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Chk2 is a serine/threonine kinase with an effector function in the
DNA damage response (DDR) pathway elicited by double-strand
breaks (DSBs). By coordinating DNA replication and repair and cell
cycle checkpoint progression, the DDR ensures proper repair of lesions
normally arising from replication errors, metabolic by-products, and
environmentalmutagens [1,2], thereby preventing genomic instability
and ultimately cancer. Upon DNA damage, Chk2 is phosphorylated
within the N-terminus S/TQ cluster domain on T68 residue by the
upstream kinase ATM [3], a product of the genemutated in the human
ataxia telangiectasia (A-T) andmaster regulator of the DDR, leading to
Chk2 homodimerization and transactivating autophosphorylation on
T383 and T387, and cis-autophosphorylation on S516 [4,5]. Once
activated, Chk2 acts as a diffusible signal transducer, phosphorylating a
multitude of substrates involved in cell cycle control, transcription,
and apoptosis. The phosphorylation of Cdc25C-Ser216 by Chk2
inhibits this phosphatase, thereby preventing the activation of Cdc2
and imposing a checkpoint arrest at multiple phases. Chk2 also
regulates the transcriptional activity and degradation of p53 by
targeting p53 on S20 and Hdmx-Ser367 [6,7], hence controlling p53-
dependent apoptosis and p21waf1-mediated cell cycle arrest. By
phosphorylating the transcription factor E2F-1 and of the transcriptionregulator Che1, Chk2 enhances the stability of these proteins and
modulates the apoptotic response to genotoxic agents [8,9]. Other
known Chk2 substrates include BRCA1 and PML with their functions
implicated in DNA repair and apoptosis [10,11]. Very recently, the
interplay between Chk2 and TRF2 has been established, whereby Chk2
phosphorylates TRF2 on telomereswhile the latter inhibits the activity
of Chk2 [12]. A connection between Chk2 and the RNA binding protein
HuR has recently deﬁned a role for Chk2 in regulating translation of
SIRT1 and c-Myc [13,14].
A number of evidences highlight the role of Chk2 as tumor
suppressor functioning in preneoplastic lesions as a barrier against
overt tumor progression by driving incipient cells to apoptosis or
senescence [15]. In line with this, inherited mutations in CHEK2 gene
confer multiorgan cancer susceptibility in various epidemiological
studies [16]. It should be noted, however, that, on its own, Chk2
manifests a weak antitumor activity based on the modest increase in
the incidence and early onset of DMBA-induced skin carcinogenesis in
Chk2 deﬁcient mice [17]. Interestingly, Chk2 modulates the response
to genotoxic chemotherapy depending on the p53 genetic back-
ground since, in the Chk2-deﬁcient setting, disruption of p53
sensitizes cells, whereas functional p53 confers resistance [18].
As genetic alterations in DDR genes can modulate the survival of
tumor cells to genotoxic treatments that cause DNA damage, such as
ionizing radiation and chemotherapy, this pathway has emerged as an
attractive pharmacologic target of therapeutic potential, prompting
the development of selective inhibitors. Accordingly, a number of
small molecule inhibitors of ATP-binding pocket of Chk2 have been
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optimization of analogues based on structure–activity relationships
and X-ray structure analysis of Chk2 in complex with inhibitors [19–
21]. We have previously reported the identiﬁcation and character-
ization of a new ATP-competitive small molecule inhibitor of Chk2,
VRX0466617 (hereafter denoted VRX) [22] and shown that it inhibits
the enzymatic activity of Chk2, both in vitro and in vivo, in cells. VRX
does not modify the cell cycle phase distribution of normal and cancer
cells after IR, but it markedly attenuates the radiation–apoptosis of
thymocytes [22]. The serine/threonine phosphatases are a conservedFig. 1. VRX induces Chk2-T68 phosphorylation in a time- and dose-dependent manner in v
(1:1000, vehicle) and analyzed byWestern blot for Chk2 phosphorylation. (B) LCL-N cells we
phosphorylation. Graphs A and B show the levels of Chk2-pT68 obtained from the densitom
independent experiments). (C) Chk2-pT68 in LCL-N, BJ-hTERT, and U2OS cells collected 90 a
90 min with VRX were separated by FACS according to DNA content, and the individual frac
G2/M-sorted fractions was veriﬁed by FACS analysis (right). exp, exponential growing.family of proteins able to regulate the reversible phosphorylation
status of the DDR protein. In particular, Wip1/PPM1D, PP1, and PP2A
are directly connected to the checkpoint regulation through the
dephosphorylatation of multiple phospho-S/TQ sites targeted [23]. In
this work, we show that, in undamaged cells, the chemical inhibition
of Chk2 kinase activity signiﬁcantly boosts the accumulation of Chk2
phosphorylated on Thr68 (Chk2-pT68), the key residue phosphory-
lated by ATM kinase following DNA damage. Besides, we demonstrate
the regulatory role of protein phosphatases in the maintaining Chk2
unphosphorylated in the absence of DNA damage.ivo. (A) LCL-N cells were incubated for the indicated times with 10 μM VRX or DMSO
re collected 90 min after treatment with escalating doses of VRX and analyzed for Chk2
etric analysis of the bands normalized for the total amount of Chk2 (data from three
nd 45 min after treatment with VRX or 10 Gy IR, respectively. (D) LCL-N cells treated for
tions were analyzed for Chk2-pT68 by Western blot (left). The purity of the G1-, S-, and
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2.1. Cell lines and treatments
The EBV-immortalized human lymphoblastoid cell line LCL-N was
from a normal individual, whereas GM07078A and AT52 (kindly
obtained from Dr Luciana Chessa) were from patients with Nijmegen
breakage syndrome (NBS) and ataxia telangiectasia (AT), respectively.
The cells were cultured in RPMI 1640 medium supplemented withFig. 2. VRX does not induce DNA damage or phosphorylation of ATM substrates. (A) Immun
(1:1000, control), VRX or IR. Nuclei were stained with DAPI (lower panel). (B) LCL-N cells we
for ATM-S1981, Smc1-S966, and p53-S15 (left) and Chk1-S317 and Chk1-S345 (right) or re
transiently transfected with Chk2wild type (HA-Chk2wt) or kinase dead (HA-Chk2kd) and co
examined by Western blot. The histogram shows the densitometric analysis of Chk2-pT6
difference between Chk2wt and Chk2kd was statistically signiﬁcant (*Pb0.01, analysis perfo15% heat-inactivated fetal calf serum (FCS). U2OS human osteosar-
coma cell lines, MCF-7 breast adenocarcinoma transfected with
shGFP or shChk2 [24], the Chk2-defective HCT15 stable transfected
with HA-Chk2 WT or KD [24], and 293FT were grown in DMEM with
10% FCS. Immortalized normal human foreskin ﬁbroblasts BJ-hTERT
were cultured in DMEM plus M199 (4:1 ratio) with 10% FCS. Culture
media contained penicillin (100 U/ml), streptomycin (100 μg/ml),
and glutamine (2 mmol/l). Cells were cultured at 37 °C in a 5% CO2
incubator. The Chk2 and ATM inhibitors VRX046617 (Valeantoﬂuorescence microscopy of γ-H2AX (upper panel) in LCL-N cells treated with DMSO
re treated with VRX or IR and analyzed byWestern blot with antibodies phosphospeciﬁc
cognizing the total forms of these proteins. (C) The Chk2-defective HCT15 cell line was
llected 45 min after treatment with 0 or 10 Gy IR and levels of total Chk2 and Chk2-pT68
8 from a different experiment, after normalization for the total amount of Chk2. The
rmed by the Student's t-test).
Fig. 3. VRX induces the phosphorylation of Chk2-T68 in an ATM-dependent manner.
(A) LCL-N cells and the ATM-defective AT52 cell line were incubated with DMSO (0.1%),
VRX (10 μM, 90 min), wortmannin (W, 50 μM, 2 hours), or wortmannin followed by
VRX. Cellswere collected at the indicated times and analyzed byWestern blot. (B) LCL-N,
AT52, and the NBS1-defective cell line GM07078A were incubated with VRX, collected
90 min later, and analyzed by Western blot (top). The histogram (bottom) shows the
densitometric analysis of the Chk2 p-T68 bands normalized for the total levels of Chk2
per lane (data from three different experiments).
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Pharmaceuticals, Cambridge, UK) [25], respectively, were prepared
as 10 mM stock solutions in DMSO and stored at −20 °C. Inhibitors
were diluted to give a maximal ﬁnal 0.1% DMSO concentration. Okadaic
acid and wortmannin were purchased from Sigma Aldrich. Irradiations
were performedwith an IBL437CO instrument (Oris Industries, France)
equipped with a 137Cs source providing 675 cGy/min.Fig. 4. Okadaic acid (OA) induces Chk2-pT68 in a time- and dose-dependent manner. (A) LC
times (left). Whole-cell extracts were analyzed by Western blot with antibodies speciﬁc for
as shown. (B) LCL-N cells were incubated with increasing concentrations of OA and analyz
90 min and analyzed by Western blot for Chk2-pT68 (C) or for Chk2-pS387, Chk2-pS33
summarized in the relative graphs, after normalization for the total amount of Chk2. (E)MCF-
(abbreviated D), OA, and VRX and were analyzed by Western blot for phosphorylation of C2.2. Western blot analysis
Untreated or treated cells were washed with PBS plus 0.1 mM
Na3VO4 (Sigma), pelleted, and lysed in Laemmli buffer (0.125 M Tris–
HCl pH 6.8, 5% SDS) containing protease and phosphatase inhibitors
(1 mM phenylmethylsulfonyl ﬂuoride [PMSF], pepstatin [10 μg/ml],
aprotinin [100 kIU/ml], leupeptin [10 μg/ml] [all from Calbiochem,
San Diego, CA], and 1 mM Na3VO4). After boiling for 5 min and
sonication, lysates were quantitated by micro-BCA assay (Pierce,
Rockford, IL). Aliquots containing 50 μg of protein plus 5% beta-
mercaptoethanol were size-fractionated on SDS–PAGE and were
electroblotted onto PVDF membranes (Millipore, Bedford, MA).
After blocking with 4% nonfat dried milk in PBS plus 0.1% Tween
20 (Sigma), membranes were incubated in sealed plastic bags with an
X-Blot hybridization equipment (Integrated Systems Engineering,
Milan, Italy; www.isenet.it) as in the study of Carlessi et al. [26], with
monoclonal antibodies for Chk2 (clone 44D4/21) [24], ATM (clone
9E6) [22], p53 (clone DO-7), β-actin (Sigma, Italy), vinculin (Sigma),
PP2A-C (a kind gift from David Pim, ICGEB, Trieste, Italy) [27], His-tag
(Invitrogen), and with rabbit antibodies speciﬁc for the phosphory-
lated Chk2-Thr387, Chk2-Thr68, Chk2-Ser19, Chk2-Ser33-35, p53-
Ser15, Chk1-Ser345, AKT-Ser473, and Erk1/2-Thr202/Tyr204 (p44/
p42 MAPK) (all from Cell Signaling Technology, Beverly, MA). Rabbit
antibodies were against PP1-C (a kind gift from Emma Villa-Moruzzi,
University of Pisa, Italy) [28], PPM1D/Wip1 (clone H300,;Santa Cruz
Biotechnology, Inc, Santa Cruz, CA), total Erk1/2 and AKT (from Cell
Signaling), Smc1-pSer966, total Smc1, Chk1-pSer317 (Bethyl Labora-
tories, Inc, Montgomery, TX), and ATM-pSer1981 (R&D Systems,
Minneapolis, MN). Binding of antibodies to membranes was detected
with peroxidase-conjugated secondary antibodies and ECL (Pierce,
Rockford, IL) on autoradiographic ﬁlms. Bands were acquired with a
digital scanner and were quantiﬁed by ImageQuant software
(Molecular Dynamics).
2.3. Expression of dominant-negative PP2A-C
Exponentially growing 293FT and U2OS cells seeded on 35-mm
plates were transfected when 70–80% conﬂuent with Lipofectamine
2000 (Invitrogen) according to the manufacturer's instructions. The
two plasmids pcDNA4-His-PP2A-C wt or dominant-negative (L199P)
were a kind gift from Stefanie Dimmeler, University of Frankfurt,
Germany [29]. The cells were then harvested and processed for
immunoblotting at the indicated time after transfection.
2.4. Knock down of PP2A-C, PP1-C, and Wip1 by siRNA
293FT cellswere seeded in 12-well dishes and transfected 18 hours
later with SiGenome Smartpool siRNA against PP1 (M00892701),
PP2A (M00359801) and Wip1 (PPM1D) (M00455400), and a
scrambled control sequence (D00121002) (all from Dharmacon)
using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer's instructions. At the indicated times, cells were harvested and
analyzed by immunoblotting.
2.5. Immunoﬂuorescence labelling
γ-H2AX nuclear foci were analyzed on treated or untreated LCL-N
cells deposited onto glass slides using a cytocentrifuge (Shandon), air-
dried, and ﬁxed in ice-cold methanol (20 min at−20 °C) and then in
acetone (2 min at −20 °C). After washing with PBS and blocking forL-N cells were treated with DMSO (1:1000), 0.5 μM OA, or 10 μM VRX for the indicated
Chk2-pT68, total Chk2, and phospho-p42/p44 (Erk1/2 and p-T202/T204, respectively)
ed as in panel A. LCL-N cells were treated with the indicated doses of OA and VRX for
-35, and Chk2-pS19 (D). Densitometric analysis of Chk2 phosphorylation bands are
7 cells stably transfected with shGFP and shChk2were incubated for 90 minwith DMSO
hk2-T68 and pERK 1/2.
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dilution of the anti H2AX-pS139 antibody clone JBW301 (Upstate
Biotechnology) and thereafter with an F(ab)2 fragment of a FITC-
conjugated secondary antibody for 1 hour (Jackson Laboratories).
After three washes in PBS, slides were counterstained with DAPI and
mounted with an antifade solution. Images were collected on a Nikon
ﬂuorescence microscope equipped with a CCD camera. Experiments
were performed three times independently on duplicate slides.
2.6. Cell sorting
LCL-N cells were incubatedwith VRX, treatedwith 10 mg/ml of the
ﬂuorescent DNA-speciﬁc permeable dye Hoechst 33342 (Calbiochem,
La Jolla, CA), and harvested 20 min later. Cells were fractionated
according to the cell cycle phases with a FACS-Vantage cell sorter
(BD Biosciences) equipped with a UV argon ion laser and a sample
refrigeration system.
2.7. Statistical analysis
Statistical analyses were performed with Student's t-test as in-
dicated in the ﬁgure legends.
3. Results
3.1. Chk2 kinase inhibition raises its phosphorylation on Thr 68
While studying the regulation of Chk2, we found in unperturbed
cells that selective inhibition of its catalytic activity with VRX0466617
(VRX) [22] promotes a rapid and striking accumulation of Chk2
phosphorylated on Thr68 (Chk2-pT68), the residue speciﬁcally
targeted by ATM kinase in response to genotoxic stress. As shown in
Fig. 1A in human LCL-N cells, Chk2-pT68 signal was detectable within
15 min of exposure to 10 μMVRX, becomingmaximal between 90 and
120 min, and was induced by as low as 0.05 μM VRX (Fig. 1B). The
VRX-induced accumulation of Chk2-pT68 was not cell line-speciﬁc
because it was also seen in U2OS and BJ-hTERT, although with
signiﬁcant differences among these cells (Fig. 1C, compare lanes 2, 5,
and 8). Although Chk2 is variably phosphorylated in the cell cycle
[24], analysis of cells treated with VRX and enriched by FACS
according to DNA content (Fig. 1D, right) showed no differences in
the levels of Chk2-pT68 among the cell cycle phases (Fig. 1D, left).
3.2. VRX induces neither DNA DSBs nor ATM-dependent checkpoint
activation
The phosphorylation of Chk2-Thr68 by ATM is a primary event in
cells treated with genotoxic agents [30]. To determine whether the
accumulation of Chk2-pT68 was the consequence of a DNA damage
inﬂicted by VRX and which would activate ATM, we assessed in LCL-N
cells the formation of γ-H2AX nuclear foci, an index of DNA damage.
In contrast to IR, VRX treatment induced neither any foci (Fig. 2A)
nor the activation of ATM, as assessed by the lack of ATM autopho-
sphorylation on Ser1981 and phosphorylation of its substrates Smc1-
S966 and p53-S15 (Fig. 2B, left), altogether suggesting that VRX
does not elicit a classical DNA damage. VRX was also unable to induce
the phosphorylation of Chk1 on S317 or S345 (Fig. 2B, right), two ATR
phosphoresidues [31–33]. Hence, neither ATM nor ATR was activated
by VRX. These ﬁndings would thus suggest that the Chk2-pT68
accumulation reﬂects a response to the inhibition of Chk2 catalytic
activity but not toDNAdamage. This is further supported byﬁndings in
the Chk2-deﬁcient HCT15 cells in which the ectopic pT68 levels are
much greater in the case of kinase-dead than wild-type Chk2 (Fig. 2C)
especially before irradiation. Thus, the accumulation of pT68 in
undamaged cells is associated with the catalytic status of Chk2,suggesting that this activity positively regulates the dephosphoryla-
tion of Chk2.
3.3. Chk2-T68 phosphorylation is prevalently ATM-dependent
Since, besides ATM, ATR and DNA-PKcs can phosphorylate Chk2
T68, we assessed in normal LCL-N and ATM-deﬁcient AT52 cells
the effect ofwortmannin at a dose that inhibits all three kinases [34,35]
on VRX-induced Chk2-pT68. When cells were preincubated with
50 μM wortmannin for 2 hours before treatment with 10 μM VRX,
Chk2-T68 phosphorylation was totally ablated (Fig. 3A, compare lanes
3 and 4). However, since in AT52 cells the pT68 signalwas still present,
although at signiﬁcantly lower level than in LCL-N cells (Fig. 3A,
compare lanes 4 and 8), these results underscore the contribution of
ATM kinase in this phenomenon. The phosphorylation of AKT-S473
was abolished by wortmannin, verifying that the dose used here is
actually inhibiting all PIK3 members [34–36]. The activity of ATM is
partly dependent on Nbs1 [37–39]. To demonstrate the role of ATM
basal activity onVRX-induced pT68,we compared the response of LCL-
N and AT52 with those of an NBS-derived cell line deﬁcient in Nbs1
expression. It can be seen (Fig. 3B) that the phosphorylation of Chk2-
T68 is reduced compared to LCL-N, albeit not to the same extent as in
AT52, again indicating the role of ATM in this response.
3.4. Okadaic acid treatment induces Chk2-pT68 accumulation
Protein serine/theronine phosphatases are implicated in the
regulation of Chk2 [40,41]. Moreover, the autophosphorylation of
ATM-S1981 and phosphorylation of Chk1-S317 and Chk1-S345 in
unirradiated cells is upregulated by concentrations of okadaic acid
(OA) that inhibit protein phosphatase 2A-like activities [42,43].
Importantly, OA induces the phosphorylation of ATM-S1981 without
causing detectable DNA damage or increase in ATM activity [42]. OA
also increases the autophosphorylation of DNA-PK [44]. Given these
evidences, we sought to determine the involvement of protein
phosphatases in the negative regulation of Chk2-T68 phosphoryla-
tion. In LCL-N cells incubated with 0.5 μM OA, detectable levels of
Chk2-pT68 became apparent at 30 min and increased signiﬁcantly up
to 120 min (Fig. 4A, left). As a positive control of the PP2A inhibition,
we assessed the MAP kinase pathway members ERK1/2 (p42/p44
MAPK) whose phosphorylation is regulated by PP2A [45,46]. In
agreement with previous reports [47,48], PP2A inhibition by OA
raised the phosphorylation of ERK1/2 (Fig. 4A), while conversely,
VRX had no effect on ERK1/2 (Fig. 4A, right), excluding this agent as
an inhibitor of PP2A. The intensity of Chk2-pT68 was OA dose-
dependent, being undetectable below 0.25 μM OA (Fig. 4B). In a
subsequent experiment, we found that even 100 nM OA is able to
induce Chk2-pT68 (Fig. 4C). Of note, OA did not induce the
phosphorylation of p53-S15, a direct substrate of ATM (Fig. 4B), con-
cordant with the fact that OA promotes the autophosphorylation but
not full enzymatic activity of ATM [42]. In contrast to VRX, OA induced
a phosphorylation-dependent mobility shift of Chk2 (Fig. 4C, arrows)
associated with Chk2 autophosphorylation on S387 and phosphory-
lation on S19 and S33-35 (Fig. 4D) [24]. Of note, VRX does not induce
the phosphorylation of these additional residues [22]. As expected, no
pT68 signal was seen in cells depleted of Chk2 (Fig. 4E), validating the
anti-pT68 for its target substrate.
3.5. PP2A, PP1, and Wip1/PPM1D phosphatases cooperatively maintain
Chk2-T68 unphosphorylated in undamaged cells
We further investigated the role of serine/threonine protein
phosphatases on Chk2 pT68 accumulation by two different ap-
proaches. In a set of experiments, cells were incubated with DMSO
alone and 10 μM VRX for 45 min or were transiently transfected
with PP2A-Cwt or PP2A-CL199P, the latter containing an amino acid
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[42,50,51]. The expression of PP2A-CL199P did not induce Chk2-pT68
accumulation inU2OS (Fig. 5A) or 292FT cells (Fig. 5B), suggesting thatFig. 5. Protein phosphatases cooperate to maintain Chk2-T68 unphosphorylated. U2OS (A) a
with either His-PP2A-C or dominant-negative His-PP2A-CL199P. Cell extracts were immunob
PPM1D/Wip1 phosphatases in 293FT cells was achieved by transfection with siRNA (scram
validated byWestern blot (C, right). After 48 hours (C, left) or 48 and 72 hours (D), cells were
P1=PP1-C, W=Wip1, scrambled=P2, P1, and W control, scrambled 2=P2+P1 control, sc
analysis of Chk2-pT68 from C and D immunoblots are shown in the bottom graphs, after no
Chk2-pT68 by Western blot (arrows indicate the antibody-speciﬁc band). The statistical sign
** (Pb0.05). All other differences were not statistically signiﬁcant (analysis performed by tPP2A-C alone does not contribute to T68 dephosphorylation. In
another set of experiments, we investigated the effects of knocking
down by siRNA the levels of PP2A-C, PP1-C, and the PP2C-membernd 293FT (B) cells were incubated with 10 μM VRX for 90 min or transiently transfected
lotted for Chk2-pT68, total Chk2, and His-tag. (C and D) Knock down of PP2A, PP1, and
bled, Scr2 and Scr3 are a negative control for the single, double, or triple silencing) and
tested for Chk2-pT68, total Chk2, PP1, and PP2A. Abbreviations to panel C: P2=PP2A-C,
rambled 3=P2+P1+W control. Legend for panel D is the same as in C. Densitometric
rmalization for total Chk2. (E) The same lysates as in D, lanes 2 and 4, were tested for
iﬁcance of the difference between siScr and siP2+P1+W is indicated by * (Pb0.01) or
he Student's t-test).
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in Fig. 5C, right. Although the accumulation of Chk2-pT68 in
undamaged cells was unaffected by these phosphatases when
individually ablated, it was markedly enhanced when all three were
simultaneously knocked down (Fig. 5C, lane 8 and graph). Similar
results were observedwhen cells were harvested at two different time
points after siRNA transfection (Fig. 5D and graph). Furthermore,
siRNA depletion of all three phosphatases signiﬁcantly raised the
levels of Chk2 phosphorylated on S387, S19, and S33-35 (Fig. 5E).
3.6. pT68 accumulation after OA treatment is only partially independent
of ATM
To determine if the induced phosphorylation of Chk2-T68 by OA
and VRX arises from the effects on a common pathway, we analyzed
the role of ATM kinase, which directly phosphorylates T68. LCL-N cells
were incubated for 90 min with VRX, OA, and KU (a selective inhibitorFig. 6. OA-induced Chk2-T68 phosphorylation is partially dependent on ATM. (A) LCL-N ce
for 45 min with 10 μM KU, lysed, and immunoblotted with the indicated antibodies. (B) LC
In panel C, AT52 cells were incubated with wortmannin (W; 50 μM for 2 hours), OA (250 nof ATM) [54] singly or in combination (in the latter case KUwas added
45 min before the other agents) and assessed Chk2 status. The results
revealed that the phosphorylation of Chk2-T68 was ATM-dependent
in response to VRX since it was abrogated by KU (Fig. 6A, compare
lane 2 with lane 5) but was only partially dependent on ATM in
response to OA (Fig. 6A, compare lanes 3 and 6). Concordant with
this, the levels of Chk2-pT68 induced by OA in the ATM-deﬁcient
AT52 cells were greatly reduced compared to LCL-N cells (Fig. 6B).
Interestingly, pretreatment of LCL-N cells with KU repressed ERK1/2
phosphorylation in response to OA (Fig. 6A, compare lanes 3 and 6),
indicating an ATM dependence of this phenomenon. Concordant with
this, the levels of OA-induced phospho-ERK1/2 in the ATM-null AT52
cells were greatly reduced relative to LCL-N (Fig. 6B, compare lanes 2
and 3 and lanes 5 and 6). Hence, these results extend the link between
the ATM activity and ERK1/2 phosphorylation not only in relation to
DNA damage [55] but also in an undamaged setting. The absence of
ATM only slightly affected OA-induced phosphorylation of T68. Tolls were treated for 90 min with 10 μM VRX and 250 nM OA, 0.1% DMSO (D, control),
L-N and AT52 were treated with OA and VRX for 90 min and processed as in panel A.
M for 90 min), wortmannin followed by OA (W+OA), or DMSO (D; 0.1%).
Fig. 7. Model for the regulation of Chk2 by protein phosphatases. (A) In undamaged
cells, owing to the basal constitutive activity of ATM, Chk2 is sufﬁciently phosphor-
ylated on T68 to elevate its catalytic activity. This, in turn might stimulate PP2A, PP1,
and Wip1 to keep in check the levels of Chk2-pT68. (B) The block of Chk2 activity by
VRX or the suppression of protein phosphatases' expression or activity by OA enhances
the accumulation of Chk2-pT68 in vivo. Thus, in the absence of DNA lesions or cell cycle
perturbations, Chk2 maintains a dephosphorylated status through the interplay with
phosphatases.
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cells were treatedwith a concentration of wortmannin that inhibits all
PI3Ks before incubating with OA. Under this condition, the OA-
induced Chk2-pT68 was not prevented by wortmannin (Fig. 6C),
excluding the dependence of this event by PI3Ks.
4. Discussion
In this work, we demonstrate that in unperturbed cells, the
catalytic inhibition of Chk2 induces a hyperphosphorylation of this
kinase on T68 [22]. The phosphorylation of Chk2-T68 is a key event in
cells responding to genotoxic stress, initiated by ATM and leading to
the autophosphorylation and full activation of Chk2 [24,30,56].
However, the phosphorylation of Chk2-T68 following its inhibition
by VRX is DNA damage-independent since, as shown here, it was not
accompanied by the formation of γ-H2AX nuclear foci, an index of
genomic DSBs, or by ATM activation as inferred from the absence of
phosphorylation of known substrates of this kinase (e.g., p53-S15 and
SMC1-S966).
In unperturbed cells, protein serine/threonine phosphatases play
a role in dephosphorylating checkpoint kinases, as in the case of
PP2A which maintains ATM and Chk1 in a hypophosphorylated
state [42,43]. To investigate the interplay of PPs with Chk2, we
ﬁrst assessed the phosphorylation of Chk2 on T68, S19, S33-35, and
T387 autophosphorylation site, upon treatment of cells with OA, a
chemical inhibitor of PP2A-like activities [42,43,49], and shown a
marked phosphorylation of Chk2 on these residues. Furthermore,
we have assessed the effects of knocking down by RNA interference
the expression of the PP2A, Wip1, and PP1 catalytic subunit
previously implicated in Chk2 phosphoregulation after DNA damage
[40,41,52,53,57]. Like the effects of OA, the simultaneous depletion
of all three phosphatases induced the accumulation of Chk2-pT68
and other phosphosites involved in its full activation, suggesting a
cooperating activity of PPs.
The intracellular accumulation of Chk2-pThr68 appeared ATM-
dependent in response to VRX but only partially dependent on ATM
in response to OA. The noncomplete ATM-dependent phosphorylation
of Chk2 suggests the contribution of an OA-sensitive kinase, as shown
in the case of Chk1 [43]. Furthermore, we excluded an off-target effect
of VRX against PPs in this response since it did not promote the
accumulation of phospho-ERK1/2 (p42-p44 MAPK), unlike OA
[47,48].
Taken together, these results suggest a regulatory model for Chk2
similar to that recently proposed for ATM and Chk1 [42,43]. We
propose that, in unperturbed cells, Chk2 regulation is under control of
both kinase and the phosphatase proteins. A low basal activity of
ATM on Chk2, perhaps due to endogenous stress, is counterbalanced
by the dephosphorylating activity of PP2A, PP2C, and Wip1. The pT68
accumulation owing to PPs repression or Chk2 kinase inhibition,
suggests a role for Chk2 activity in a negative loop through which it
restrains and ﬁnely tunes Chk2 kinase, also to avoid an inappropriate
Chk2 activation in the presence of minimal amounts of DNA lesions
(Fig. 7). In perturbed cells, this negative feedback loop destabilizes,
allowing the build up of an optimal DNA damage response, but how
this occurs remains unclear. Given that the activation of Chk2 involves
transient dimerization partly through intermolecular pT68–FHA
domain interactions, one possibility is that this might impair the
afﬁnity of PPs for Chk2 and/or enhance their dissociation [57],
allowing the kinase to become fully active. Our results concord with
others showing a role for PPs in the dephosphorylation of targets
involved in DDR and checkpoint recovery, like PP2A, which regulates
the autophosphorylation of ATM on Ser1981 without promoting its
kinase activity [42,58], Chk1 [43], p53 [59], and γ-H2AX [60].
Moreover, Wip1/PPM1D dephosphorylates Chk1, Chk2, γ-H2AX,
and p53 [53,61,62], while ATM-regulated PP1 activity [63] acts on
p53 [64] and on Chk2-dependent phosphorylation of Brca1 [65].In conclusion, our work provides a detailed characterization of the
phosphorylative regulation of Chk2 in unperturbed cells and under-
scores the role of PPs in keeping, through feedback mechanisms, the
ground state of activation of the ATM/Chk2 circuit, whose inappro-
priate deregulation can induce growth arrest, apoptosis, premature
ageing, and senescence.
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